Drug Trial Radar · NCT05041101
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jun 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
6
Actual
Start
Dec 21, 2021
Primary completion
Sep 6, 2024
Study completion Sep 6, 2024
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase Ib/II trial tests the safety and side effects of grapiprant and eribulin and whether they work to shrink tumors in patients with inflammatory breast cancer that has spread to other places in the body (metastatic). Grapiprant is an anti-inflammatory drug that may prevent tumor growth. Eribulin may block tumor cell growth by stopping tumor cell division. Giving grapiprant and eribulin together may help to control the disease.
Conditions
- Breast Inflammatory Carcinoma
- Recurrent Breast Inflammatory Carcinoma
- Stage IV Breast Inflammatory Carcinoma
Interventions
Eribulin MesylateDrug
Given IV
GrapiprantDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the Safety of Grapiprant and Eribulin Combination TreatmentTime frame: Up to 21 days from the initial treatment
- Determine the Efficacy of Grapiprant and Eribulin Combination TreatmentTime frame: Up to 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
M D Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.